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Abstract
Background/Aims: Most heart failure (HF) hospital discharges involve people > 65 years, many frail. The
purpose of this study was to determine if frailty explains variability in health related quality of life (HRQOL)
in older adults with HF over and above known correlates.
Methods: A frailty index score was developed by weighting age, number of comorbid conditions, and
symptom severity. A multivariate hierarchical regression analysis of known predictors of HRQOLgender,
income, ethnicity, health perception, NYHA class — were entered first and then the frailty index was entered
and regressed on HRQOL in 2 unique samples.
Results: When known predictors were tested on a sample they explained 11% (p 0.14) of the variance in
HRQOL; when the frailty index score was added 24% (p 0.001) was explained. When the index was validated
in a second sample, known predictors explained 15% (p 0.04) of the variance; with the frailty index score 40%
(p 0.000) was explained.
Conclusion: Frailty explains significant amounts of variance in HRQOL in HF. Treating comorbid conditions
and controlling symptoms may improve HRQOL in HF patients. These findings support the need for further
research into the impact of frailty on HRQOL in HF patients.
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Abstract 
Background/Aims: Most heart failure (HF) discharges involve people > 65 years, many frail.  
The purpose of this study was to determine if frailty explains variability in health related quality 
of life (HRQOL) in older adults with HF over and above known correlates. 
  
 
Methods: A frailty index score was developed by weighting age, number of comorbid 
conditions, and symptom severity.  A multivariate hierarchical regression analysis of known 
predictors of HRQOL- gender, income, ethnicity, health perception, NYHA class – were entered 
first and then the frailty index was entered and regressed on HRQOL in 2 unique samples. 
Results:  When known predictors were tested on a sample they explained 11% (p 0.14) of the 
variance in HRQOL; when the frailty index score was added 24% (p 0.001) was explained.  
When the index was validated in a second sample, known predictors explained 15% (p 0.04) of 
the variance; with the frailty index score 40% (p 0.000) was explained.   
Conclusion: Frailty explains significant amounts of variance in HRQOL in HF.  Treating 
comorbid conditions and controlling symptoms may improve HRQOL in HF patients.  These 
findings support the need for further research into the impact of frailty on HRQOL in HF 
patients. 
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Introduction 
Globally, cardiovascular disease (CVD) is the number one cause of morbidity and 
mortality in both developed and developing countries
1
.  In the United States
2
 (US) and most 
European countries
1
 CVD is also a disease of aging.  Almost two thirds of the six million people 
discharged from the hospital in the US with CVD are 65 years of age or older
2
.  In particular, 
73% of those discharged with the diagnosis of heart failure (HF) were over the age of 65 
2
.  The 
development of a chronic syndrome, like HF, can precipitate concurrent frailty
3
.   Frailty, defined 
as a state of risk or vulnerability brought about by co-occurring, multiple system deterioration 
resulting in adverse outcomes, is highly prevalent in the older adult population 
3-6
.   Because 
multiple systems are compromised and regulating one system may affect another,  frail, older 
adults with HF are at risk for increased hospitalizations
7
.  A further negative outcome common is 
poor health related quality of life (HRQOL), an issue that is already particularly problematic for 
older adults with HF 
8
.  Frail older adults with HF are frequently hospitalized increasing their 
risk for additional deficits. 
Each one of these older adults hospitalized with HF was cared for by a nurse, many of 
whom specialize in cardiovascular nursing.  Cardiovascular nurses also provide expert care to 
HF patients in outpatient settings.  But are these nurses equally prepared to recognize frailty and 
care for older adults?  While frailty has been studied and discussed extensively in the geriatric 
literature, reference to frailty is limited in the cardiovascular literature 
3, 5, 6
.  Further exploration 
is needed to determine whether there is a relationship between frailty and HRQOL, individually 
and in relation to both morbidity and mortality 
4, 9, 10
.   Therefore, the purpose of this study was to 
explore the relationship between frailty and HRQOL in older HF patients. 
  
 
Frailty in Heart Failure  
 Frailty is currently understood in one of two ways.  One way defines frailty as a clinical 
syndrome based on selected physical indicators resulting in vulnerability 
4
.  A second way 
defines frailty as a multi-factorial state of deficits accumulated over the life course 
3
.  Fried and 
colleagues 
4
 developed a phenotype of frailty using data from the Cardiovascular Health Study.  
Frailty, as a clinical syndrome, was said to be present if a person presented with three or more of 
the following symptoms: an unintentional weight loss of 10 lbs in the past year, weakness 
measured via grip strength, fatigue, decreased activity, or slowed walking speed.  In 
cardiovascular samples, frailty is most commonly found in those with multiple comorbid 
conditions
11
.  About half of a community dwelling sample of over 5,000 older persons met the 
criteria for frail (3 or more indicators) or near frail (1 or 2 indicators).  Frailty was associated 
most strongly with age and a history of HF (odds ratio 7.51, 95% confidence interval 4.66 – 
12.12) 
12
.  In another study of 670 community dwelling women, cardiovascular disease (CVD) 
increased the risk of frailty in those with mild anemia.  A significant multiplicative interaction 
was found between hemoglobin level and CVD status with respect to the risk of frailty when 
controlling for age and other covariates.  Chaves and colleagues 
13
 theorized that CVD 
diminished the effectiveness of compensatory responses to anemia resulting in increased 
vulnerability.   
Frailty is associated with disability but differentiated by its biologic antecedents of 
decreased physiologic reserve and resistance to stressors, while disability is understood to 
involve an inability to perform certain activities.  Fried and colleagues 
4
 found only a modest 
concordance between frailty and disability but that there was a significant stepwise increase in 
  
 
disability as frailty increased.  In persons with HF, frailty has been found to predict falls, 
disability, hospitalization, and death 
4, 9
. 
Health Related Quality of Life in Heart Failure 
HRQOL is a subjective, multidimensional construct that links physical, psychological, 
and social well-being with the ability to carry out the activities of daily living 
14
.  In HF, 
subjective variables like symptoms, functional status, anxiety and health perception are 
consistently associated with HRQOL with more symptoms, poorer functional status, greater 
anxiety scores and poor health perception associated with poorer HRQOL 
15-19
.  More objective 
indices like ejection fraction, B-type natriuretic peptide (BNP), and jugular venous distention 
have not been found to have a direct effect on HRQOL 
17, 18
.    
HRQOL impacts morbidity, mortality, and treatment choices for patients.  In a Spanish 
sample, worsening HRQOL predicted hospital readmission and mortality for HF patients at a 
frequency comparable to other well known predictors such as a history of diabetes or treatment 
with an angiotensin converting enzyme inhibitor 
10
.    Patients with poorer HRQOL are more 
willing to trade survival time and take risks in treatment choices than those with better HRQOL 
20, 21
.   
From the literature it can be theorized that there is a relationship between frailty and 
HRQOL.  The relationship between frailty and disability
4
 in addition to the relationship between 
functional status and HRQOL
8
 supports the hypothesis that there would be a relationship 
between frailty and HRQOL.  However, no study was found that examined this hypothesis.  
Therefore, in this secondary analysis we explored this relationship between frailty and HRQOL 
in persons with HF after accounting for known determinants of HRQOL. 
  
 
 Building on our previous work which was tested in another end stage disease population, 
we continue to explore whether a framework in which quality of life is the primary outcome is 
applicable in other disease populations
22
.  In this framework variability in HRQOL is explained 
by both fixed and modifiable dimensions of the domains of the patient’s lived experience.  The 
domains are physiological, psychological, social/cultural, and spiritual/existential.  The measured 
indicators for the fixed dimensions need to be accounted for but the indicators for the modifiable 
dimensions, depending on whether they directly or inversely impact HRQOL, need to be either 
supported or ameliorated.  For this study frailty is conceptualized as including indicators for both 
fixed and modifiable dimensions for the physiological domain – the patient’s age and number of 
comorbid conditions are fixed while symptom severity is modifiable and therefore amenable to 
interventions focused on improving quality of life.   
Methods 
 In this secondary analysis frailty was conceptualized as a construct measured using the 
person’s age at time of enrollment into the study, number of comorbid conditions, and a total 
severity score for three symptoms prevalent in this population – fatigue, dyspnea on exertion, 
and chest pain.  Age was obtained by self-report.  Comorbid conditions were measured using the 
17-item Charlson Comorbidity Index, which generates a total possible score ranging from 0-30.  
A higher score indicates a higher level of comorbid disease 
23
.  The symptom scale asked the 
person to rank each symptom (fatigue, dyspnea on exertion, chest pain) on a 1-10 scale with the 
anchors, 1 = very mild and 10 = worst imaginable.  Zero was entered if the symptom was not 
reported. 
 The index was formed by weighting these three indicators (age, comorbidity, symptoms) 
using weights derived from an analysis performed in a benchmark sample of 130 older adults 
  
 
with HF who had been accrued for a previous intervention study
24
.  The individual items were 
regressed on the total Minnesota Living with Heart Failure Questionnaire (MLHFQ) score and 
then the unstandardized coefficients and the constant from that regression were used to derive the 
weights for the new frailty index. Potential contamination between the MLHFQ score and the 
three indicators was assessed by examining collinearity statistics.  Residual statistics and 
influence were also analyzed.  The regression equation was Predicted MLHFQ total score = (66 
+ (age x -0. 597) + (symptom severity x 1.426) + (comorbidity score x 1.38)).   The index was 
then confirmed in a second sample which was split into two unique groups to test and validate 
the stability of the findings.  Known determinants of HRQOL were accounted for in all analyses.   
Sample 
 The benchmark sample participants were accrued from two Southern California hospitals 
24
.  The test sample was from five hospitals in the same area 
25
.  The recruitment of the 
participants and procedures have been described in detail elsewhere, but in brief, HF patients 
were enrolled during hospitalization, half received a disease management intervention, and all 
were followed for 6 months
24, 25
.  The test sample was divided in half with one half used to test 
the index (Test sample one) and the second half used to validate the stability of the index (Test 
sample two).   Both the benchmark and test samples were hospitalized with a primary diagnosis 
of HF at the time of enrollment and able to speak English or Spanish.  Patients with an obvious 
cognitive impairment, an untreated psychiatric illness, or a terminal disease, were excluded as 
were those on renal dialysis and those being discharged to a long term care facility.  Only 
baseline data collected at enrollment were used to develop and test the frailty index. This 
investigation conformed with the principles outlined in the Declaration of Helsinki
26
. 
Measurement 
  
 
 HRQOL was measured by the total score on the  MLHFQ 
27
. The MLHFQ, used widely 
in HF research, asks the person to rate the impact (0 = no impact to 5 = most severe impact) of 
their condition or its treatment on various aspects of daily life.  The items are additive, yielding a 
total score of 0-105, with a lower score reflecting less impact or better HRQOL.  For this study 
the Cronbach’s alpha for the two test samples was 0.92.    
 Demographics (i.e. gender, ethnicity, marital status, education level, work status, and 
income) were obtained by self-report. Health perception was measured by a one item question 
asking the person to rate his or her health (1 = much worse to 5 = much better) as compared with 
a year ago. 
Data Analysis 
 Multivariate hierarchical regression modeling was conducted using SPSS version 15.0 
28
.  
Predictors of HRQOL were identified from the literature.  Two model blocks (1
st
 block: NYHA 
class, ethnicity, income, health perception, and gender; 2
nd
 block: new frailty index) were tested 
with HRQOL as the dependent variable on Test sample one and then validated with Test sample 
two.  A p value of less than 0.05 was accepted as statistically significant.  Collinearity statistics 
and residual statistics were scrutinized.   
Results 
Characteristics of the Sample 
 In the benchmark sample used to develop the frailty index, a total of 130 older adults, 
median age 72 years, 98% NYHA III or IV HF were included.  Test sample one included a total 
of 97 unique persons, median age 76 years, 87% NYHA class III or IV HF.  Test sample two 
included 75 additional persons, median age 72 years, 92% NYHA class III or IV HF.  In the test 
sample participants were likely to be female, married, white, retired, finished high school, and 
  
 
lower income.   Differences between the benchmark sample and the test sample were analyzed 
using chi square with a  Bonferroni adjustment to control for Type I errors, a p of 0.007 was 
necessary for significance.  Individuals in the benchmark sample were more likely than the two 
test samples to be Hispanic, NYHA Class IV, with less than a 7
th
 grade education, and make 
under $10,000 (US ) a year in income.  See Tables 1 and 2 for additional demographic 
information and the means (standard deviations) on the frailty index for all samples.  
Effect of Known Predictors and Frailty Index on HRQOL 
 For the benchmark sample, the zero-order and partial correlations for age show that when 
symptoms (fatigue, dyspnea, and chest pain) and number of comorbid conditions are controlled, 
age has less influence on MLHFQ total (Table 3).  Similar findings result for symptoms when 
controlling for age and comorbidity as well as for comorbidity when age and symptoms are 
controlled.  The semi-partial correlations show that when assessing the unique amount of 
variance accounted for by age, symptoms, or comorbidity on MLHFQ total, age and symptoms 
continue to show a moderate amount of correlation.  Due to this moderate correlation, 
collinearity statistics were examined before the analysis continued.  Tolerance and its inverse 
(variance inflation factor) are within accepted limits (Table 3).  The same analysis was 
conducted on Test sample one and Test sample two.  Inspection of the residual statistical output 
for the benchmark sample showed that while at least one prediction was more than two standard 
deviations below the mean residual(-2.45)  there was no undue influence exerted with maximum 
leverage of 0.09.  In Test sample one the standardized residual was -2.18 (max leverage 0.54) 
and for Test sample two the standardized residual was -2.36 (max leverage 0.52). 
Using multivariate hierarchical regression, known predictors of HRQOL - NYHA class, 
ethnicity, income, health perception, and gender were regressed upon the total MLHFQ score in 
  
 
the first block.  The frailty index was then entered in the second block.  In Test sample one and 
two the frailty index significantly increased the amount of variability predicted for HRQOL 
(Table 4).  The standardized β show that when the other predictors are held constant that 
MLHFQ total score will, on average, increase 0.37 SD (Test sample one) and 0.54 SD (Test 
sample two) when the frailty index increases one standard deviation.  A higher MLHFQ total 
score denotes lower HRQOL for the patient. 
Discussion 
In this study we examined the relationship of frailty and HRQOL in older adults with HF.  
We found that when frailty was measured as a composite of age, number of comorbid conditions, 
and symptom status a significant amount of variability in HRQOL was explained over and above 
know determinants of HRQOL.  While 627 publications were found citing Fried and colleagues 
4
 
seminal work on developing a phenotype of frailty in the geriatric population, this is the first 
study of HRQOL and frailty in community dwelling older adults with HF. This study supports 
the importance of nurses being aware of and assessing the risk for frailty in older adult with HF 
but it also provides easily obtained indicators for assessing for the presence of frailty in their 
patients.  When these frailty indicators are present the nurse can then implement evidence based 
best practice protocols to address the risk to decreased quality of life that they represent.  This 
frailty index combines both current conceptualizations of frailty (clinical syndrome, 
multifactorial state) into a clinically useful measurement.   
Age and frailty are linked but distinct phenomena 
3, 6
.  Heterogeneity in the older adult 
population may account for the differences between age and frailty.  While older adults with HF 
report poorer HRQOL than age matched healthy groups 
8
 it is less clear whether age alone 
effects HRQOL in HF.  As this study showed, when number of comorbid conditions and 
  
 
symptoms were held constant the influence of age decreased.  Two recent studies in HF 
populations found that while not the strongest predictor, age, did predict HRQOL when analyzed 
with other independent variables – with older patients reporting better HRQOL29, 30.   This 
finding is supported in other disease populations, such as oncology, where older adults generally 
report higher quality of life and less symptom distress even when they have greater numbers of 
comorbid diseases and more symptom burden than younger persons at the same disease stage 
31, 
32
.  The weighting of age in this index shows that it is less explanatory of frailty than the other 
two indicators – number of comorbid conditions and symptom severity. 
Conceptually, comorbidity has been suggested as a mediator between physiological 
processes and clinical outcomes 
33
.   HF patients are also known to be more likely to have 
diabetes
11
, renal failure
34
, and depression
35
 in addition to other comorbidities
36
.  The number of 
comorbid conditions is known to be related to frailty 
4, 37
.   Perhaps the metabolic stress placed 
on the body by multiple disease processes in the presence of diminishing metabolic reserves may 
potentiate the osteopenia and sarcopenia noted as hallmarks of frailty
38
.  In this study the number 
of comorbid conditions contributes more to the frailty index than age but not as much as 
symptom severity.   
It has been suggested that chronic symptoms are seen by the older adult as normal in 
aging 
32
.  However, in this study we showed that rating higher severity on the three symptoms 
found most frequently in HF – fatigue, dyspnea on exertion, and chest pain – contribute to 
frailty, perhaps by limiting activity, which may set up a negative feedback system whereby the 
decreased activity leads to greater risk for increased frailty and decreased HRQOL.  Morley, 
Perry, and Miller 
38
 have developed a model to explain the etiology of frailty in older adults.  
They proposed that pain is one precursor that leads to inactivity, then sarcopenia, and finally, 
  
 
frailty.  Additional etiologic factors suggested are malnutrition, atherosclerosis, cognitive 
impairment and social factors
38
.  The relationships between age, symptoms, and HRQOL found 
in this study is supported by previous work conducted in adults with HF by Heo and colleagues 
29
. 
While there is extensive literature on quality of life in the oncology and geriatric 
populations, in comparison, there is a paucity of work exploring the predictors of HRQOL in 
cardiac patients.  Prior to 2000, HRQOL was a rare primary endpoint in HF clinical trial
14, 39
.  In 
the intervening years, those studies that have assessed HRQOL found poorer HRQOL to be 
directly or indirectly associated with NYHA functional class, depression, number of medications, 
serum creatinine, and lower ejection fraction 
10, 15, 17, 40
.  Together, these isolated predictors could 
be thought of as indicators of frailty, a conceptual leap that would move the field forward. 
Bekelman and colleagues 
16
, in a NYHA class II population, found 32% of the variance 
in HRQOL was explained by the number of symptoms.  Our study supports the increasing 
importance of the symptom experience as the individual declines by using a mostly NYHA class 
III and IV population, while also accounting for two other well known predictors of HRQOL – 
age and number of comorbid conditions.  Bekelman used the Memorial Symptom Assessment 
Scale –short form (MSAS) which assesses the presence, severity, and distress caused by 25 
symptoms common in patients.  It is interesting to note that while the version of the MSAS used 
by these researchers was not developed for cardiac patients, the top three symptoms reported in 
Bekelman’s study were shortness of breath, lack of energy, and pain (area not specified).  Our 
symptom severity score included fatigue and shortness of breath while assessing for specific 
cardiac (chest) pain.  
  
 
 Heo and colleagues found that gender, work status, affective state, and symptom status 
all predicted HRQOL 
8, 18, 41
.  Furthermore, subjective variables – health perception and symptom 
status, were stronger predictors of HRQOL than more objective variables like disease etiology 
and number of comorbidities.  A model inclusive of a single item health perception question, 
symptom status, and age explained 29% of the variance in the total MLHFQ 
18
.  The difference 
in the findings between our study and Heo and colleagues’ may be related to the developed 
frailty index.  Age, symptom severity, and number of comorbid conditions are weighted 
differently to reflect their known influence on HRQOL.   
Quality of life has been described as reflecting the totality of the individual’s experiences 
and perceptions over time but also to depend on the time at which it is measured 
42
.   As to 
whether subjective quality of life is a state (situationally determined) or trait (dispositionally 
determined) measure needs further exploration.  Cummins 
43
 suggests that each individual has a 
normative level of subjective well-being which is generally positive and insensitive to gradual 
and low levels of degradation.   However, he suggests that current atheoretical 
conceptualizations and poor measurement of quality of life hinder the advancement of the 
science.    Cummins goes on to recommend that further work in the area  include: 1) agreement 
in quality of life measurement as to which variables are indicator and which are causal, 2) 
organization of indicator variables hierarchically from general to specific, and 3) development of 
instruments based on this hierarchy.  Our study addressed these two critiques of quality of life 
research by designing the study based on a conceptual model and using a well validated 
instrument (MLHFQ) to measure quality of life. 
One strength of this study is its theoretical foundation.  Previous work on the conceptual 
framework had shown that QOL was directly and inversely related to fixed and modifiable 
  
 
dimensions of the older adult’s disease experience domains (physiological and 
spiritual/existential) in an oncology population
22
.  When this study was designed, HRQOL was 
conceptualized as an outcome variable explained by similar fixed and modifiable dimensions of 
the physiological domain in a HF population. The relationship of HRQOL and frailty (measured 
as a composite of age, number of comorbid conditions, and symptom severity) was theorized a 
priori to be negatively related based on the literature and this conceptual framework.  The 
findings of the data analyses in this study supported these hypotheses.  As frailty increases, 
HRQOL decreases.  While this study was conducted in one end stage disease population – 
individuals with HF, it is recommended that the index be tested in other populations to broaden 
its applicability. 
A further strength relates to the methodology used in testing the frailty index.  Prior to 
data analysis contamination between the individual items (age, symptoms, comorbidities and the 
MLHFQ total score) was assessed by a careful examination of multicollinearity and residual 
statistics.  Because both the symptom scale and the MLHFQ contain items related to intensity of 
symptoms, care was taken to assess for potential collinearity.   Only when no significant issue 
was found did the analysis continue.  In addition, the decision to use a second unique sample 
(Test sample two) to validate the findings from the first test sample (Test sample one) 
strengthens the evidence supporting the findings of this study.  The diversity of the samples in 
which the index was tested and then validated suggests additional strength and applicability of 
this index.  While there were significant differences between the benchmark sample and the two 
test samples in relation to functional status (NYHA class), socioeconomic status (income and 
education), and ethnicity the frailty index continued to explain significant amounts of HRQOL.  
Furthermore, there were differences between the two test samples.  In Test sample one, health 
  
 
perception’s beta coefficient (0.20) shows its relative importance in relation to the other 
predictors in that regression equation, while in Test sample two, income (-0.28) has the largest 
beta coefficient.  This suggests that this index could be used in diverse populations.  It is 
recommended that further testing take place. 
There are several limitations to the current study.  As a secondary data analysis, the 
variables available in the data set may not have been the strongest indicators of frailty.  The 
phenotype developed by Fried and colleagues 
4
 involved objective biometric measurements – 
weight loss, grip strength, 15 feet walking time as well as the subjective measures of self-report 
exhaustion and kilocalories expended.  For our study all of the variables in the frailty index were 
self-reported.  It is recommended that a future, prospective longitudinal study measure the 
phenotypic criteria of frailty in current use – unintentional weight loss greater than 10 pounds, 
weakened grip strength, slowed pace of walking, subjective fatigue, and decreased physical 
activity 
4
 – and compare the relationship of those indicators for frailty with HRQOL to explore 
which measure is more pragmatic and predictive.   
The question has been raised as to whether quality of life is better measured as an 
independent or dependent variable
44
.  What is the temporal relationship between frailty and 
HRQOL?  Does frailty predict HRQOL or HRQOL predict frailty? While age and number of 
comorbid conditions are fixed dimensions of the patient’s experience, do the patient’s 
perceptions of whether their life has quality shape their experience of physical limitations?  
These questions cannot be answered with the cross sectional data in this study.  Future studies 
involving longitudinal measurement should explore the causal relationship between frailty and 
HRQOL.   
  
 
A further limitation relates to the instrument used to measure HRQOL.  The Minnesota 
Living with Heart Failure Questionnaire is a commonly used measure in this population
48
.  
However, questions have been raised as to its sensitivities to subtle differences and psychometric 
soundness 
45, 46
.   A broader measure of quality of life, measuring not only health related quality 
of life, but inclusive of existential and cultural domains might provide a deeper understanding of 
the true impact of frailty on day to day quality of life for the older adult with HF.  Finally, 
secondary analysis suffers from any limitations that may have existed in the original study.  
Concerns related to the validity and reliability of the measurement in the parent study, whether 
concerning instrumentation or language, may call into question any findings in the secondary 
analysis.  However, in this analysis, the original studies were conducted by experienced and 
respected researchers and were published in peer-reviewed journals. 
Conclusion 
Heart failure is an increasingly prevalent syndrome in the frail older adult population
49
.  
Independently, both HF and frailty have been shown to increase the risk of repeat, unplanned 
hospitalizations, increased health care costs, and death.  This study has shown that frailty 
negatively impacts HRQOL for the older adult with HF.  As frailty increases, the negative 
influences on HRQOL increase and people report lower HRQOL.  As treatment preferences can 
be influenced by perceived HRQOL, it is important for cardiovascular nurses to assess for frailty.  
This frailty index score provides a means for the clinician to assess for frailty at the point of care.  
In an older person with multiple comorbid conditions, as well as HF, reports of dyspnea, fatigue, 
and pain should be addressed by nurses with evidence based symptom palliation.  Recent 
recommendations are available and should be integrated in to current best practice standards
47
.   
The findings of this study also support the need for future research into the impact with frailty on 
  
 
HRQOL to determine whether interventions aimed at addressing the modifiable dimensions of 
the HF patient’s lived experience will improve heath related quality of life. 
  
 
References 
1. Cardiovascular diseases. 2010; 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html. 
2. Older Americans and cardiovascular diseases - statistics2010. 
3. Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical 
paradigm--issues and controversies. J Gerontol A Biol Sci Med Sci. Jul 2007;62(7):731-
737. 
4. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. 
J Gerontol A Biol Sci Med Sci. Mar 2001;56(3):M146-156. 
5. Lunney JR, Lynn J, Hogan C. Profiles of older medicare decedents. J Am Geriatr Soc. 
Jun 2002;50(6):1108-1112. 
6. Bortz WM, 2nd. A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med 
Sci. May 2002;57(5):M283-288. 
7. Goodlin SJ. Heart failure in the elderly. Expert Rev Cardiovasc Ther. Jan 2005;3(1):99-
106. 
8. Heo S, Moser DK, Lennie TA, Zambroski CH, Chung ML. A comparison of health-
related quality of life between older adults with heart failure and healthy older adults. 
Heart Lung. Jan-Feb 2007;36(1):16-24. 
9. Rich MW. Heart failure in the oldest patients: the impact of comorbid conditions. The 
American Journal of Geriatric Cardiology. 2007;14(3):134-141. 
10. Rodriguez-Artalejo F, Guallar-Castillon P, Pascual CR, et al. Health-related quality of 
life as a predictor of hospital readmission and death among patients with heart failure. 
Arch Intern Med. Jun 13 2005;165(11):1274-1279. 
11. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women 
with coronary disease. Circulation. Sep 14 2004;110(11):1424-1430. 
12. Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical 
cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. Mar 
2001;56(3):M158-166. 
13. Chaves PH, Semba RD, Leng SX, et al. Impact of anemia and cardiovascular disease on 
frailty status of community-dwelling older women: the Women's Health and Aging 
Studies I and II. J Gerontol A Biol Sci Med Sci. Jun 2005;60(6):729-735. 
14. al-Kaade S, Hauptman PJ. Health-related quality of life measurement in heart failure: 
challenges for the new millennium. J Card Fail. Jun 2001;7(2):194-201. 
15. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with 
congestive heart failure: comparison with other chronic diseases and relation to 
functional variables. Heart. Mar 2002;87(3):235-241. 
16. Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression, and quality of 
life in patients with heart failure. J Card Fail. Oct 2007;13(8):643-648. 
17. Rector TS. A conceptual model of quality of life in relation to heart failure. J Card Fail. 
Apr 2005;11(3):173-176. 
18. Heo S, Moser DK, Riegel B, Hall LA, Christman N. Testing a published model of health-
related quality of life in heart failure. J Card Fail. Jun 2005;11(5):372-379. 
19. Hofer S, Doering S, Rumpold G, Oldridge N, Benzer W. Determinants of health-related 
quality of life in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 
Jun 2006;13(3):398-406. 
  
 
20. MacIver J, Rao V, Delgado DH, et al. Choices: a study of preferences for end-of-life 
treatments in patients with advanced heart failure. J Heart Lung Transplant. Sep 
2008;27(9):1002-1007. 
21. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for 
quality of life or survival expressed by patients with heart failure. J Heart Lung 
Transplant. Sep 2001;20(9):1016-1024. 
22. Buck HG, Overcash, J., & McMillan, S.C. The geriatric cancer experience in end of life: 
Testing an adapted model. Oncol. Nurs. Forum. 2009 (in press). 
23. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by 
questionnaire rather than medical record review? Med Care. Jan 1996;34(1):73-84. 
24. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D, Unger A. Effect of a standardized 
nurse case-management telephone intervention on resource use in patients with chronic 
heart failure. Arch Intern Med. Mar 25 2002;162(6):705-712. 
25. Riegel B, Carlson B, Glaser D, Hoagland P. Which patients with heart failure respond 
best to multidisciplinary disease management? J Card Fail. Dec 2000;6(4):290-299. 
26. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. 
Declaration of Helsinki. Br Med J. Jul 18 1964;2(5402):177. 
27. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with 
Heart Failure questionnaire: reliability and validity during a randomized, double-blind, 
placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am 
Heart J. Oct 1992;124(4):1017-1025. 
28. SPSS Graduate Pack 15.0 for Windows with AMOS 7.0 [computer program]2006. 
29. Heo S, Doering LV, Widener J, Moser DK. Predictors and effect of physical symptom 
status on health-related quality of life in patients with heart failure. Am J Crit Care. Mar 
2008;17(2):124-132. 
30. Lewis EF, Lamas GA, O'Meara E, et al. Characterization of health-related quality of life 
in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J 
Heart Fail. Jan 2007;9(1):83-91. 
31. Hwang SS, Chang VT, Cogswell J, et al. Study of unmet needs in symptomatic veterans 
with advanced cancer: incidence, independent predictors and unmet needs outcome 
model. J. Pain Symptom Manage. Nov 2004;28(5):421-432. 
32. McMillan SC, Small BJ. Symptom distress and quality of life in patients with cancer 
newly admitted to hospice home care. Oncol. Nurs. Forum. Nov-Dec 2002;29(10):1421-
1428. 
33. Yancik R, Ershler W, Satariano W, Hazzard W, Cohen HJ, Ferrucci L. Report of the 
national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci. Mar 
2007;62(3):275-280. 
34. Shlipak MGSJAGDLFWNKFCDH, Estrogen/progestin Replacement Study I. Renal 
insufficiency and cardiovascular events in postmenopausal women with coronary heart 
disease. Journal of the American College of Cardiology. Sep 2001;38(3):705-711. 
35. Albert NM, Fonarow GC, Abraham WT, et al. Depression and clinical outcomes in heart 
failure: an OPTIMIZE-HF analysis. American Journal of Medicine. Apr 
2009;122(4):366-373. 
36. Zambroski CH, Moser DK, Roser LP, Heo S, Chung ML. Patients with heart failure who 
die in hospice. Am Heart J. Mar 2005;149(3):558-564. 
  
 
37. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress 
and quality of life in patients with advanced congestive heart failure. J Pain Symptom 
Manage. Jun 2008;35(6):594-603. 
38. Morley JE, Perry HM, III, Miller DK. Editorial: Something About Frailty. J Gerontol A 
Biol Sci Med Sci. November 1, 2002 2002;57(11):M698-704. 
39. Garin O, Ferrer M, Pont A, et al. Disease-specific health-related quality of life 
questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res. 
Feb 2009;18(1):71-85. 
40. Hooley PJ, Butler G, Howlett JG. The relationship of quality of life, depression, and 
caregiver burden in outpatients with congestive heart failure. Congest Heart Fail. Nov-
Dec 2005;11(6):303-310. 
41. Heo S, Moser DK, Widener J. Gender differences in the effects of physical and emotional 
symptoms on health-related quality of life in patients with heart failure. Eur J Cardiovasc 
Nurs. Jun 2007;6(2):146-152. 
42. Walters SJ, Campbell MJ, Lall R. Design and analysis of trials with quality of life as an 
outcome: a practical guide. J. Biopharm. Stat. 2001;11(3):155-176. 
43. Cummins RA. Moving from the quality of life concept to a theory. J. Intellect. Disabil. 
Res. Oct 2005;49(Pt 10):699-706. 
44. Cummins RA. Moving from the quality of life concept to a theory. Journal of Intellectual 
Disability Research. Oct 2005;49(Pt 10):699-706. 
45. Riegel B, Moser DK, Glaser D, et al. The Minnesota Living With Heart Failure 
Questionnaire: sensitivity to differences and responsiveness to intervention intensity in a 
clinical population. Nurs Res. Jul-Aug 2002;51(4):209-218. 
46. Heo S, Moser DK, Riegel B, Hall LA, Christman N. Testing the psychometric properties 
of the Minnesota Living with Heart Failure questionnaire. Nurs Res. Jul-Aug 
2005;54(4):265-272. 
47. Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative care in the treatment 
of advanced heart failure. Circulation. Dec 22 2009;120(25):2597-2606. 
48. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and 
symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 
Sep 2005;4(3):198-206. 
49. Leventhal MJ, Riegel B, Carlson B, De Geest S. Negotiating compliance in heart failure: 
remaining issues and questions. Eur J Cardiovasc Nurs. Dec 2005;4(4):298-307. 
 
  
Table 1. 
Demographic Characteristics 
Benchmark 
sample  
n= 130 
Test sample one 
n=  97 
Test sample two 
n= 75 
Difference 
between 
Benchmark 
and Sample 
groups   
 
Percent     Mean   
(SD) 
Percent    Mean 
(SD) 
Percent    Mean 
(SD) 
p 
Age 70 (13.1) 74 (10.9) 71 (11.7)  
 Range 39-95 Range 24-91 Range 20-95  
Gender 
     Male 
     Female 
 
54% 
46% 
 
47% 
53% 
 
43% 
57% 
 
 
Marital status 
     Married 
     Widowed 
     Single 
     Divorced/separated 
 
45% 
30% 
  8% 
17% 
 
51% 
37% 
  3% 
  9% 
 
50% 
29% 
  7% 
14% 
 
Ethnicity 
     Caucasian 
     Hispanic 
 
73% 
27% 
 
98% 
  2% 
 
98% 
  2% 
0.000 
Education 
     Less than 7
th
 grade 
     Grade school 
     High school 
     Business school 
     2 year college 
     4 year college 
     Graduate school 
 
28% 
  6% 
32% 
  7% 
16% 
  6% 
  5% 
 
  2% 
  9% 
49% 
  5% 
16% 
11% 
  8% 
 
  1% 
11% 
51% 
  5% 
13% 
14% 
  5% 
0.000 
Work 
     Homemaker 
     Fulltime 
     Part time 
     Disabled or retired for health reasons 
     Retired for non-health reasons 
     Unemployed 
 
  8% 
  7% 
  5% 
25% 
45% 
10% 
 
  8% 
  2% 
  5% 
28% 
52% 
  5% 
 
11% 
  5% 
  9% 
30% 
40% 
  5% 
 
Income 
     Less than 10,000 
     10,000-14.999 
     15,000-19,999 
     20,000-29,999 
     30,000-44,999 
     45,000 or more 
 
34% 
26% 
11% 
  7% 
  8% 
14% 
 
13% 
18% 
25% 
22% 
14% 
  8% 
 
22% 
22% 
16% 
17% 
11% 
12% 
0.002 
NYHA 
     II 
     III 
     IV 
 
  2% 
36% 
62% 
 
13% 
56% 
31% 
 
  8% 
48% 
44% 
0.000 
 1 
  2 
  
Table 2. 
Mean and Standard Deviations for the Frailty Index Score by Sample  
Sample Mean (SD) N 
Benchmark sample 50.98 (13.96) 130 
Test sample one 39.40 (12.29) 97 
Test sample two 42.32 (12.14) 75 
 1 
  2 
  
Table 3. 
Proportion of Variance and Multicollinearity Analysis 
Correlations with MLHFQ 
a
 total 
Zero-
order
b 
Partial
c Semi-
partial
d 
Tolerance Variance Inflation 
Factor 
Benchmark  Sample  
Age -0.39 -0.38 -0.33 0.99 1.01 
Symptoms  0.48  0.47  0.42 0.96 1.04 
Comorbidity  0.21  0.13  0.10 0.97 1.04 
Test sample one 
Frailty Index 0.42 0.37 0.35 0.91 1.10 
Test sample two 
Frailty Index 0.55 0.55 0.50 0.88 1.13 
a 
Minnesota Living with Heart Failure Questionnaire; 
b 
zero-order correlation – raw correlation; 1 
c 
partial correlation –correlation of the given variable with MLHF total controlling for other 2 
independent variables;
 d 
semi-partial correlation – correlation of the given variable with MLHF 3 
total controlling only for the effect of the other independent variables on the given variable 4 
 5 
  6 
  
Table 4.  
 
Regression Analyses of Predictors of HRQOL and Frailty Index 
 Variable          (mean, SD) Standardized β t R2  F change p 
        
Test 
sample 
one Gender 0.02 0.14 0.11  1.73 0.14 
 Income -0.11 -0.94     
 Ethnicity -0.04 -0.36     
 NYHA 
a 
  0.09 0.86     
 Health Perception -0.20 -1.83     
 Frailty Index    (39.4, 12.3) 0.37 3.32 0.24  11.03 0.001 
 MLHFQ
b
          (49.6, 23.8)       
Test 
sample 
two Gender -0.07 -0.70 0.15  2.45 0.04 
 Income -0.28 -2.74     
 Ethnicity -0.13 -1.26     
 NYHA
a
  -0.07 -0.74     
 Health Perception 0.03 0.30     
 Frailty Index    (42.3, 13.1) 0.54 5.37 0.40  28.82 0.000 
 MLHFQ
b
          (53.7, 24.8)       
a
 New York Heart Association, 
b 
Minnesota Living with Heart Failure Questionnaire 1 
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